OXiGENE (OXGN) Reports First Quarter 2013 Financial Results
5/7/2013 9:56:53 AM
More...
|
OXiGENE (OXGN) Announces $5 Million Private Placement
4/11/2013 12:07:11 PM
More...
|
OXiGENE (OXGN) Appoints Dai Chaplin, Ph.D., to Its Board of Directors
1/24/2013 9:29:42 AM
More...
|
OXiGENE (OXGN) Regains Nasdaq Closing Bid Price Compliance
1/16/2013 9:10:35 AM
More...
|
OXiGENE (OXGN) Announces Presentation of Encouraging OXi4503 Preclinical and Clinical Data in Acute Myelogenous Leukemia at American Society of Hematology Meeting
12/10/2012 9:07:13 AM
More...
|
OXiGENE (OXGN) Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease, Polypoidal Choroidal Vasculopathy (PCV), Presented at the American Academy of Ophthalmology 2012 Annual Meeting
11/12/2012 2:39:11 PM
More...
|
OXiGENE (OXGN) Reports Third Quarter 2012 Financial Results
11/9/2012 10:09:26 AM
More...
|
OXiGENE (OXGN) Announces Presentation at BIO-Europe Conference on November 14th
11/6/2012 9:43:56 AM
More...
|
OXiGENE (OXGN) Announces Agreement With FDA on Special Protocol Assessment for a Phase 3 Trial of ZYBRESTAT® in Anaplastic Thyroid Cancer
9/18/2012 9:45:55 AM
More...
|
OXiGENE (OXGN) to Present Data Showing Importance of Local Site Pathology Confirmation in Phase 2/3 Clinical Trial of Zybrestat® in Anaplastic Thyroid Cancer
9/7/2012 9:58:05 AM
More...
|
|